Applications of Fmoc-(S)-3-Amino-4-(4-Chloro-Phenyl)-Butyric Acid in Industrial Manufacturing

Fmoc-(S)-3-Amino-4-(4-Chloro-Phenyl)-Butyric Acid supports modern peptide synthesis, drug research, and pharmaceutical advanced intermediates. This specialty amino acid derivative plays a critical role in solid-phase peptide manufacturing, specialty pharma ingredient production, and analytical peptide standards development. Our manufacturing approach ensures material integrity for sensitive processes involving bioactive peptide chains and related complex molecules.

1. Solid-Phase Peptide Synthesis (SPPS) for Pharmaceutical Peptides

SPPS processes rely on high-purity, chiral amino acid building blocks protected by Fmoc groups. In large-scale peptide drug production, this raw material ensures secure residue incorporation and strictly defined side chain characteristics, especially for bioactive peptides targeting CNS or oncology. Production aligns with regulated GMP environments, demanding traceable quality management and validation. Our facility supplies differentiated specification grades to meet peptide Active Pharmaceutical Ingredient (API) requirements for clinical and commercial supply chains.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 211 (for drug substances used in human therapeutics)
• EU EudraLex Volume 4: GMP Guidelines
• EP, USP, JP pharmacopoeial monographs for amino acid derivatives (where applicable)

Typical usage ratio

• Used as one residue per target peptide sequence; generally 1 eq. per coupling cycle on solid support
• Overall batch consumption determined by chain length and batch size; usage optimized by coupling efficiency (90-99%)

Downstream process integration

• Enters at the protected residue addition phase during automated or manual SPPS on resin
• Cleavable after final peptide assembly; Fmoc group removed during piperidine treatment step
• Material QC tested for purity, isomeric content, and residual solvent before use in peptide synthesis reactors

Final product types

• Therapeutic peptide APIs (e.g., neuropeptide analogs, peptide hormone mimetics)
• Clinical trial peptide lots
• Generic peptide compounds for pharma research
• Peptide reagents for preclinical or toxicity studies

2. Custom Peptide Reference Standard Preparation

Certified laboratories use this protected amino acid in synthetic pathways for peptide reference materials. These standards enable rigorous analytical method validation for pharmaceutical release and impurity profiling. Our stringent control over chiral purity and side chain substitution supports reliable certified reference material (CRM) production. Laboratories demand exact mass and sequence fidelity, making the selection and traceability of building blocks critical.

Industry compliance standards

• ISO 17034:2016 (General requirements for the competence of reference material producers)
• Ph. Eur. Section 5.12 on reference standards
• USP General Chapter <1040> on analytical reference standards
• Compliance with GLP for batch records and documentation

Typical usage ratio

• 0.5 to 2 mmol per custom peptide batch, aligned to target peptide length and analytical scale
• Fine-tuned based on peptide molar requirements for distinct analytical applications

Downstream process integration

• Added at residue-specific assembly points in automated peptide synthesizer runs
• Material identity and assay checked by HPLC, MS before sequence assembly
• Final crude reference products undergo purification (often by preparative HPLC) and full characterization

Final product types

• Peptide CRMs for pharmaceutical laboratories
• Analytical standards for impurity profiling by LC-MS or UPLC
• Stability and shelf-life test standards
• Calibration peptides for mass spectrometry

3. Pharmaceutical Intermediate Synthesis for Advanced APIs

The raw material acts as a key intermediate for the assembly of complex small-molecule drugs, especially where precise stereochemistry and chloro-phenyl substitution confer specific receptor binding. Pharmaceutical manufacturers integrate the amino acid into multi-step organic syntheses, where controlled Fmoc deprotection and amide coupling form the backbone of investigational new drug (IND) and commercial ingredient pathways. Rigorous lot consistency and residue traceability enable scale-up in regulated production settings.

Industry compliance standards

• Current Good Manufacturing Practice (CGMP, 21 CFR Part 210 & Part 211)
• ICH Q11 (Development and Manufacture of Drug Substances)
• EU REACH registration (for industrial and pharmaceutical intermediates)
• Documentation for full traceability in drug master files (DMF, EDMF)

Typical usage ratio

• Integrated at stoichiometric levels according to the synthetic route; typically 1:1 with downstream acid chloride or coupling partners
• Batch size calculated by API process demand; adjust for step yield and purity control

Downstream process integration

• Added at critical amide bond-forming step; monitored by in-process HPLC and NMR
• Fmoc group removed prior to downstream cyclization or additional functionalization steps
• Intermediate QC checked for enantiopurity, residual Fmoc, and moisture content

Final product types

• Small-molecule active intermediates for CNS, oncology, or metabolic disorder drugs
• Chiral intermediates supplied under GMP for API synthesis
• Precursor molecules for further side chain elaboration
• Protected amino acid derivatives for regulated drug manufacturing

4. Peptidomimetic and Drug Discovery Library Development

In combinatorial chemistry and pharmaceutical research, Fmoc-protected amino acid derivatives are essential for building peptidomimetic libraries. Discovery teams use these compounds for high-throughput screening campaigns targeting protease inhibitors, GPCR modulators, or enzyme substrates. The precise stereochemistry, side chain properties, and Fmoc protection deliver reliable scaffold construction. Our consistent supply ensures researchers can expand analog series and hit validation with confidence in raw material performance.

Industry compliance standards

• OECD Guidelines for the Testing of Chemicals, Section 5: Good Laboratory Practice
• US FDA 21 CFR Part 58 (GLP for nonclinical laboratory studies)
• Corporate research material specification protocols
• Documentation for substance traceability in discovery workflows

Typical usage ratio

• 0.1 to 1 mmol per analog in library; ratio varies with automated synthesis platform throughput
• Optimized by overall library size, intended scaffold diversity, and resource allocation

Downstream process integration

• Fed into parallel synthesis modules; first added during resin loading or first coupling
• Fmoc group selectively removed at each synthetic iteration as scaffold complexity increases
• Material QC tracked throughout sequence extension and final screening assays

Final product types

• Peptidomimetic libraries for HTS (high-throughput screening)
• Lead compound series for drug discovery programs
• Fragment-based drug design building blocks
• Specialty screening reagents for target identification